Literature DB >> 19509230

Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation.

Gro Vatne Røsland1, Agnete Svendsen, Anja Torsvik, Ewa Sobala, Emmet McCormack, Heike Immervoll, Josef Mysliwietz, Joerg-Christian Tonn, Roland Goldbrunner, Per Eystein Lønning, Rolf Bjerkvig, Christian Schichor.   

Abstract

Human mesenchymal stem cells (hMSC) aid in tissue maintenance and repair by differentiating into specialized cell types. Due to this ability, hMSC are currently being evaluated for cell-based therapies of tissue injury and degenerative diseases. However, extensive expansion ex vivo is a prerequisite to obtain the cell numbers required for human cell-based therapy protocols. Recent studies indicate that hMSC may contribute to cancer development and progression either by acting as cancer-initiating cells or through interactions with stromal elements. If spontaneous transformation ex vivo occurs, this may jeopardize the use of hMSC as therapeutic tools. Whereas murine MSC readily undergo spontaneous transformation, there are conflicting reports about spontaneous transformation of hMSC. We have addressed this controversy in a two-center study by growing bone marrow-derived hMSC in long-term cultures (5-106 weeks). We report for the first time spontaneous malignant transformation to occur in 45.8% (11 of 24) of these cultures. In comparison with hMSC, the transformed mesenchymal cells (TMC) showed a significantly increased proliferation rate and altered morphology and phenotype. In contrast to hMSC, TMC grew well in soft agar assays and were unable to undergo complete differentiation. Importantly, TMC were highly tumorigenic, causing multiple fast-growing lung deposits when injected into immunodeficient mice. We conclude that spontaneous malignant transformation may represent a biohazard in long-term ex vivo expansion of hMSC. On the other hand, this spontaneous transformation process may represent a unique model for studying molecular pathways initiating malignant transformation of hMSC.

Entities:  

Mesh:

Year:  2009        PMID: 19509230     DOI: 10.1158/0008-5472.CAN-08-4630

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  213 in total

Review 1.  Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

2.  Adipose-derived mesenchymal stromal cells from genetically modified pigs: immunogenicity and immune modulatory properties.

Authors:  Goutham Kumar; Hidetaka Hara; Cassandra Long; Humza Shaikh; David Ayares; David K C Cooper; Mohamed Ezzelarab
Journal:  Cytotherapy       Date:  2012-01-23       Impact factor: 5.414

3.  Defining the probability that a cell therapy will produce a malignancy.

Authors:  Darwin J Prockop
Journal:  Mol Ther       Date:  2010-07       Impact factor: 11.454

Review 4.  Bone marrow mesenchymal stem cells: historical overview and concepts.

Authors:  Pierre Charbord
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

5.  Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells.

Authors:  Benjamin L Larson; Joni Ylostalo; Ryang H Lee; Carl Gregory; Darwin J Prockop
Journal:  Tissue Eng Part A       Date:  2010-07-13       Impact factor: 3.845

6.  Editorial: The imperative to authenticate cell lines.

Authors:  John H Healey
Journal:  Clin Orthop Relat Res       Date:  2010-12       Impact factor: 4.176

Review 7.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

8.  A shorter telomere is the key factor in preventing cultured human mesenchymal stem cells from senescence escape.

Authors:  Liu He; Yong Zheng; Yu Wan; Jian Song
Journal:  Histochem Cell Biol       Date:  2014-09       Impact factor: 4.304

9.  Convergence of normal stem cell and cancer stem cell developmental stage: Implication for differential therapies.

Authors:  Shengwen Calvin Li; Katherine L Lee; Jane Luo; Jiang F Zhong; William G Loudon
Journal:  World J Stem Cells       Date:  2011-09-26       Impact factor: 5.326

10.  Osteogenic differentiation of 3D cultured mesenchymal stem cells induced by bioactive peptides.

Authors:  Vera Lukasova; Matej Buzgo; Vera Sovkova; Jana Dankova; Michala Rampichova; Evzen Amler
Journal:  Cell Prolif       Date:  2017-08       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.